Covid-19: World's first human challenge trials to start in UK
Healthy, young volunteers will be infected with coronavirus to test vaccines and treatments in the world's first Covid-1...
Healthy, young volunteers will be infected with coronavirus to test vaccines and treatments in the world's first Covid-19 "human challenge" study, which will take place in the UK.The study, which has received ethics approval, will start in the next few weeks and recruit 90 people aged 18-30.They will be exposed to the virus in a safe and controlled environment while medics monitor their health.The UK has given doses of a Covid vaccine to more than 15 million people.Human challenge studies have played a vital role in pushing the development of treatments for a number of diseases, including malaria, typhoid, cholera and flu.
View SourceThis notice has been removed
The content is no longer available
Healthy, young volunteers will be infected with coronavirus to test vaccines and treatments in the world's first Covid-19 "human challenge" study, which will take place in the UK.The study, which has received ethics approval, will start in the next few weeks and recruit 90 people aged 18-30.They will be exposed to the virus in a safe and controlled environment while medics monitor their health.The UK has given doses of a Covid vaccine to more than 15 million people.Human challenge studies have played a vital role in pushing the development of treatments for a number of diseases, including malaria, typhoid, cholera and flu.
No results found
Try a different search term
Something went wrong
No notices yet
No notices match these filters
Couldn't load notices
You're all caught up 🎉
Sign in to continue to Global Noticeboard
Enter your email to receive a reset link
Create a new password for your account
You are marking this Notice are inappropriate, and you belive it infringes on the Global Noticeboard Community Guidelines (link). Is this so?
Create 3 Noticeboards to earn this Silver level Community Champion Badge.
View all badges that you can earnPlease tell us why you are reporting this content.
Discussion (0)
No comments yet